

Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort

S.M. Laville, M. Metzger, B. Stengel, C. Jacquelinet, C. Combe, D. Fouque, M. Laville, L. Frimat, C. Ayav, E. Speyer, B.M. Robinson, Z.A. Massy, S. Liabeuf

British Journal of Clinical Pharmacology

Corresponding author:

Bénédicte Stengel

Director, Inserm U1018, Team 5

UPS-UVSQ, CESP, Centre for Epidemiology and Population Health

EpReC Team, Renal and Cardiovascular Epidemiology


16, avenue P. Vaillant Couturier

94 807 Villejuif cedex

France

Phone: + 33 1 4559 5039

E-mail: benedicte.stengel@inserm.fr



Supplementary Figure 2: Percentage of patients with at least one contraindicated antidiabetic prescription, at least one inappropriately high dose antidiabetic prescription or at least one inappropriate antidiabetic prescription, according to the summary of product characteristics (SPC), the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines¹ and the European Renal Best Practice (ERBP) guidelines².

¹ National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. *Am. J. Kidney Dis.* 60, 850–886 (2012).

² Guideline development group. Clinical Practice Guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR <45 mL/min). *Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc.* 30 Suppl 2, ii1-142 (2015).